Citations

Showing 10 of 108081 citations.

Is thalamic deep brain stimulation synergistic with vagus nerve stimulation in drug‐resistant genetic generalized epilepsy?
Khan, Aafreen , Middlebrooks, Erik H. , Freund, Brin , Grewal, Sanjeet S. , Tatum, William O. , Grewal, Sanjeet , Middlebrooks, Erik H

Mayo Clinic

Epileptic Disorders | March 20, 2023 | Volume: 25 | Issue: 3 | Pages: 406-409

10.1002/epd2.20038 | PMID 36938890 Get It

AbstractNeuromodulation in epilepsy is a proven treatment for people with drug‐resistant focal epilepsy. Dual device therapies are increasingly utilized in people with drug‐resistant epilepsy. Vagus nerve stimulation (VNS) and deep brain stimulation (DBS) target the thalamus involving the primary neurobiological network in patients with genetic generalized epilepsy (GGE). We report a novel case of combined neuromodulation in a patient with drug‐resistant GGE who achieved a partial response with seizure reduction after VNS implantation yet following VNS‐DBS polyneurostimulation gradually achieved prolonged seizure freedom. We speculate that by combining the indirect activating effects of VNS with the direct inhibitory effects of DBS, this may provide synergy to thalamic modulated networks. We hypothesize a “rational polytherapy” may exist in some patients with GGE undergoing dual neuromodulation.
Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations
Mangaonkar, Abhishek A. , Patnaik, Mrinal M.

Mayo Clinic

American Journal of Hematology | March 20, 2023 | Volume: 98 | Issue: 6 | Pages: 951-964

10.1002/ajh.26915 | PMID 36938794 Get It

AbstractCondition OverviewClonal hematopoiesis (CH) refers to age‐associated expansion of somatic variants in hematopoietic stem and progenitor cells (HSPC).DiagnosisCH of indeterminate potential (CHIP) is operationally defined as pathogenic variants in HSPCs at a variant allele frequency ≥2%.Clinical AssociationsCH is associated with increased occurrence of several hematological conditions such as cytopenias (also called clonal cytopenia of undetermined significance), hematological (predominantly myeloid but also lymphoid) neoplasms, cytosis (including monocytosis), and non‐hematological conditions such as atherosclerotic cardiovascular and cerebrovascular disease, ischemic congestive heart failure, venous thromboembolism, type 2 diabetes mellitus, chronic obstructive pulmonary disease, osteoporosis, gout, with a potential protective effect in Alzheimer's disease (AD).Management RecommendationsAs of now, there is limited prospective data for CH testing; however, CH detection is becoming increasingly prevalent due to ubiquitous use of somatic and germline NGS testing. This in addition to data suggesting that therapy related myeloid neoplasm (tMN) in many cases is preceded by the detection of CH clones, has led to the establishment of CH clinics at several institutions. At our institution, on a research basis, we currently recommend testing for CH for individuals with persistent (≥4 months) unexplained cytopenias, in patients with malignancies prior to adjuvant cytotoxic chemotherapy and/or radiation or radionuclide therapy, screening prior to autologous hematopoietic stem cell transplantation and chimeric antigen receptor T cell (CAR‐T) therapy and to assess as to whether or not, potential germline mosaic variants actually represent CH.
Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
Shah, Vishal , McNatty, Andrea , Simpson, Lacey , Ofori, Henry , Raheem, Farah , Shah, Vishal

Mayo Clinic

Biomedicines | March 20, 2023 | Volume: 11 | Issue: 3 | Pages: 950

10.3390/biomedicines11030950 | PMID 36979929 Get It

Objective: This study is a comprehensive review of the clinical pharmacology, pharmacokinetics, efficacy, safety, and clinical applicability of amivantamab-vmjw for metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutation. Data Synthesis: The literature search to identify clinical trials returned only the CHRYSALIS phase 1 study. In a phase I trial, amivantamab-vmjw was associated with an overall response rate (ORR) of 40% (95% CI, 29–51) in the EGFR exon20ins NSCLC patient population (n = 81) after platinum-based chemotherapy. There were 3 complete responses (CRs) and 29 partial responses (PRs). The median duration of response (DOR) was 11.1 months (95% CI, 6.9—not reached; NR). The median progression-free survival (PFS) was 8.3 months (95% CI, 6.5–10.9), and overall survival (OS) was 22.8 months (95% CI, 14.6—NR). Application to Clinical Practice: This review summarizes the pharmacology, clinical evidence, and use of amivantamab-vmjw for patients with locally advanced or metastatic NSCLC with EGFR exon20ins mutation. Conclusion: The FDA approval of amivantamab-vmjw, the first bispecific antibody to target the exon20ins mutation, represents an important advancement in the treatment of patients with NSCLC with limited effective treatment options. The initial findings of the CHRYSALIS trial demonstrate an overall tumor response benefit with an acceptable safety profile.
Emerging targets for therapy in ALD: Lessons from NASH
Singal, Ashwani K. , Shah, Vijay H. , Malhi, Harmeet , Malhi, Harmeet , Singal, Ashwani K

Mayo Clinic

Hepatology | March 20, 2023 | Volume: 80 | Issue: 1 | Pages: 223-237

10.1097/hep.0000000000000381 | PMID 36938877 Get It

Alcohol-associated liver disease due to harmful alcohol use and NAFLD associated with metabolic syndrome are the 2 most common liver diseases worldwide. Control of respective risk factors is the cornerstone in the long-term management of these diseases. Furthermore, there are no effective therapies. Both diseases are characterized by metabolic derangements; thus, the focus of this review was to broaden our understanding of metabolic targets investigated in NAFLD, and how these can be applied to alcohol-associated liver disease. Conserved pathogenic pathways such as dysregulated lipid metabolism, cell death pathways including apoptosis and activation of innate immune cells, and stellate cells mediate both alcohol and NAFLDs, resulting in histological abnormalities of steatosis, inflammation, fibrosis, and cirrhosis. However, pathways such as gut microbiome changes, glucose metabolism and insulin resistance, inflammatory signaling, and microRNA abnormalities are distinct in these 2 diseases. In this review article, we describe conserved and distinct pathogenic pathways highlighting therapeutic targets that may be of potential in both diseases and those that are unique to each disease.
Advances in reconstructive urology: A review of the 2022 literature
Bearrick, Elizabeth , Simhan, Jay , Sterling, Joshua , Nikolavsky, Dmitriy

Mayo Clinic

International Journal of Reconstructive Urology | March 20, 2023 | Volume: 1 | Issue: 1 | Pages: 4-11

10.4103/ijru.ijru_3_23 Get It

ABSTRACT Reconstructive urology encompasses a broad spectrum of lower and upper urinary tract diseases. A recent society of genitourinary reconstructive mission statement emphasized the desire to promote and support research in the growing fields of tissue engineering, device design, patient-reported outcomes, and validated measurement tools for urethral stricture disease. The purpose of this article was to identify and highlight the high-impact recent literature published within reconstructive urology during the past year. Original research, systematic reviews, and videos from the Gold Journal, BJUI, World Journal of Urology International, SIU Journal, Neurourology Urodynamics, Journal of Urology, and European Urology were included.
Mitochondrial Base Editing: Recent Advances towards Therapeutic Opportunities
Kar, Bibekananda , Restrepo-Castillo, Santiago , Sabharwal, Ankit , Ekker, Stephen C. , Castillo, Santiago R , Ekker, Stephen C , Sabharwal, Ankit , Kar, Bibekananda , Clark, Karl J.

Mayo Clinic

International Journal of Molecular Sciences | March 20, 2023 | Volume: 24 | Issue: 6 | Pages: 5798

10.3390/ijms24065798 | PMID 36982871 Get It

Mitochondria are critical organelles that form networks within our cells, generate energy dynamically, contribute to diverse cell and organ function, and produce a variety of critical signaling molecules, such as cortisol. This intracellular microbiome can differ between cells, tissues, and organs. Mitochondria can change with disease, age, and in response to the environment. Single nucleotide variants in the circular genomes of human mitochondrial DNA are associated with many different life-threatening diseases. Mitochondrial DNA base editing tools have established novel disease models and represent a new possibility toward personalized gene therapies for the treatment of mtDNA-based disorders.
Molecular Mechanisms Underlying TNFα-Induced Mitochondrial Biogenesis in Human Airway Smooth Muscle
Dasgupta, Debanjali , Bhat, Sanjana Mahadev , Price, Alexis L. , Delmotte, Philippe , Sieck, Gary C. , Mahadev Bhat, Sanjana , Sieck, Gary , Delmotte, Philippe , Dasgupta, Debanjali

Mayo Clinic

International Journal of Molecular Sciences | March 20, 2023 | Volume: 24 | Issue: 6 | Pages: 5788

10.3390/ijms24065788 | PMID 36982859 Get It

Proinflammatory cytokines such as TNFα mediate airway inflammation. Previously, we showed that TNFα increases mitochondrial biogenesis in human ASM (hASM) cells, which is associated with increased PGC1α expression. We hypothesized that TNFα induces CREB and ATF1 phosphorylation (pCREBS133 and pATF1S63), which transcriptionally co-activate PGC1α expression. Primary hASM cells were dissociated from bronchiolar tissue obtained from patients undergoing lung resection, cultured (one–three passages), and then differentiated by serum deprivation (48 h). hASM cells from the same patient were divided into two groups: TNFα (20 ng/mL) treated for 6 h and untreated controls. Mitochondria were labeled using MitoTracker green and imaged using 3D confocal microscopy to determine mitochondrial volume density. Mitochondrial biogenesis was assessed based on relative mitochondrial DNA (mtDNA) copy number determined by quantitative real-time PCR (qPCR). Gene and/or protein expression of pCREBS133, pATF1S63, PCG1α, and downstream signaling molecules (NRFs, TFAM) that regulate transcription and replication of the mitochondrial genome, were determined by qPCR and/or Western blot. TNFα increased mitochondrial volume density and mitochondrial biogenesis in hASM cells, which was associated with an increase in pCREBS133, pATF1S63 and PCG1α expression, with downstream transcriptional activation of NRF1, NRF2, and TFAM. We conclude that TNFα increases mitochondrial volume density in hASM cells via a pCREBS133/pATF1S63/PCG1α-mediated pathway.
Inflammation, Infiltration, and Evasion—Tumor Promotion in the Aging Breast
Cruz-Reyes, Nicole , Radisky, Derek C.

Mayo Clinic

Cancers | March 20, 2023 | Volume: 15 | Issue: 6 | Pages: 1836

10.3390/cancers15061836 | PMID 36980723 Get It

Breast cancer is a significant cause of morbidity and mortality in women, with over two million new cases reported worldwide each year, the majority of which occur in post-menopausal women. Despite advances in early detection and treatment, approximately one-third of patients diagnosed with breast cancer will develop metastatic disease. The pathogenesis and progression of breast cancer are influenced by a variety of biological and social risk factors, including age, ethnicity, pregnancy status, diet, and genomic alterations. Recent advancements in breast cancer research have focused on harnessing the power of the patient’s adaptive and innate immune systems for diagnostic and therapeutic purposes. The breast immune microenvironment plays a critical role in regulating tissue homeostasis and resistance to tumorigenesis. In this review, we explore the dynamic changes in the breast immune microenvironment that occur with age, how these changes impact breast cancer development and progression, and how targeted therapeutic interventions that leverage the immune system can be used to improve patient outcomes. Our review emphasizes the importance of understanding the complex interplay between aging, the immune system, and breast cancer, and highlights the potential of immune-based therapies in the fight against this devastating disease.
The Role of Telemedicine in Prehospital Traumatic Hand Injury Evaluation
Carter, Rickey E. , Guliyeva, Günel , Torres‐Guzman, Ricardo A. , Maita, Karla C. , Ho, Olivia A. , TerKonda, Sarvam P. , Forte, Antonio J. , Bruce, Charles J. , Torres, Ricardo A , Forte, Antonio Jorge , Carter, Rickey E , Ávila, Francisco R. , McLeod, Christopher J.

Mayo Clinic

Diagnostics | March 20, 2023 | Volume: 13 | Issue: 6 | Pages: 1165

10.3390/diagnostics13061165 | PMID 36980474 Get It

Unnecessary ED visits and transfers to hand clinics raise treatment costs and patient burden at trauma centers. In the present COVID-19 pandemic, needless transfers can increase patients’ risk of viral exposure. Therefore, this review analyzes different aspects of the remote diagnosis and triage of traumatic hand injuries. The most common file was photography, with the most common devices being cell phone cameras. Treatment, triage, diagnosis, cost, and time outcomes were assessed, showing concordance between teleconsultation and face-to-face patient evaluations. We conclude that photography and video consultations are feasible surrogates for ED visits in patients with traumatic hand injuries. These technologies should be leveraged to decrease treatment costs and potentially decrease the time to definitive treatment after initial evaluation.
Migraine Patient Care Model Preferences in a Community Practice
Stern, Jennifer I. , Ebbert, Jon O. , Young, Nathan P. , Young, Nathan P , Vierkant, Robert A.

Mayo Clinic

Neurology Clinical Practice | March 19, 2023 | Volume: 13 | Issue: 2 | Pages: No page available

10.1212/cpj.0000000000200131 | PMID 37064592 Get It